Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Long-Term Investments (2016 - 2020)

Tenax Therapeutics' Long-Term Investments history spans 3 years, with the latest figure at $1.8 million for Q4 2017.

  • On a quarterly basis, Long-Term Investments fell 78.93% to $1.8 million in Q4 2017 year-over-year; TTM through Dec 2017 was $1.8 million, a 78.93% decrease, with the full-year FY2017 number at $1.8 million, down 78.93% from a year prior.
  • Long-Term Investments hit $1.8 million in Q4 2017 for Tenax Therapeutics, down from $2.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for TENX hit a ceiling of $19.6 million in Q2 2016 and a floor of $1.8 million in Q4 2017.
  • Historically, Long-Term Investments has averaged $9.6 million across 3 years, with a median of $6.9 million in 2016.
  • Biggest five-year swings in Long-Term Investments: crashed 52.35% in 2016 and later plummeted 86.83% in 2017.
  • Tracing TENX's Long-Term Investments over 3 years: stood at $18.0 million in 2015, then crashed by 52.35% to $8.6 million in 2016, then plummeted by 78.93% to $1.8 million in 2017.
  • Business Quant data shows Long-Term Investments for TENX at $1.8 million in Q4 2017, $2.3 million in Q3 2017, and $3.3 million in Q2 2017.